


Clinical and Physiologic Evidence Supports the Role of CGRP in Migraine Pathophysiology



Plasma CGRP levels increase during a migraine attack and return to normal after using a triptan.^{1,2}




CGRP is elevated in saliva and tears during an acute migraine attack.^{4,5}



CGRP receptors are found in the trigeminal ganglion, cerebral and meningeal vasculature, trigeminal nucleus caudalis, and thalamus.⁶⁻⁸



CGRP infusion can induce migraine-like headaches in people who have migraines.³




CGRP receptors are found on neurons, vascular smooth muscle, glia, and mast cells.⁶⁻⁹

CGRP Receptors Are Localized on Cells and in Areas Associated With Migraine Pathophysiology



Smooth muscle cells

CGRP binds to receptors on smooth muscle and mast cells and causes meningeal and cerebral blood vessel vasodilation and inflammation



Mast cells

CGRP release in the trigeminovascular system triggers events that lead to migraine pain



Neurons and glial cells

Meninges

Cerebral Cortex

Thalamus

Trigeminal ganglion

Trigemincervical complex (TCC)

Neck muscles and joints


Cortical areas process input from TCC manifesting as migraine pain and symptoms

The migraine pain signal is relayed through the brainstem into the brain


CGRP-CGRP-R Signaling in Migraine Pathophysiology May Involve Multiple Central and Peripheral Nervous System Processes

Research has yet to determine which, if any, of these processes may be causal. The relationship may be correlative or unrelated.


Peripheral



Vasodilation¹⁻³



Nociceptor Sensitization¹⁻³




Neurogenic inflammation¹⁻³

Central



Cortical-spreading depression^{1,3}



Trigeminal sensory activation³



Central sensitization³



Hypothalamic dysfunction activating meningeal nociceptors and lowering pain thresholds⁴

Pharmacologic Support for the Role of CGRP in Migraine Pathophysiology

Triptans¹

- Inhibit CGRP release induced by trigeminal activation
- Constrict CGRP-dilated vessels
- Normalize CGRP levels
- Increase serotonin release

Selective serotonin (5-HT_{1F}) agonist (ditans)²

- Inhibits CGRP release

Anti-CGRP monoclonal antibodies^{2,3}

- Block CGRP actions
- Prevent sustained trigeminal nerve firing

Onabotulinumtoxin A³

- Inhibits CGRP release
- Downregulates receptors on nociceptive neurons

Small-molecule CGRP receptor antagonists (gepants)¹

- Inhibit CGRP binding
- Block pain amplification and perpetuation processes

Ergots²

- Activate 5-HT_{1D} receptors on intracranial blood vessels
- Increase 5-HT_{1D} receptor expression on trigeminal sensory nerve ending
- Constrict CGRP-dilated vessels
- Inhibit CGRP release